![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | C07K 14/725 | (2006.01) |
A61K 38/46 | (2006.01) | ||
A61K 35/17 | (2015.01) | ||
C12N 5/0783 | (2010.01) | ||
C12N 9/22 | (2006.01) | ||
A61K 35/76 | (2015.01) | ||
A61K 39/00 | (2006.01) |
(11) | Number of the document | 3774871 |
(13) | Kind of document | T |
(96) | European patent application number | 19721447.1 |
Date of filing the European patent application | 2019-04-11 | |
(97) | Date of publication of the European application | 2021-02-17 |
(45) | Date of publication and mention of the grant of the patent | 2023-06-28 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2019/027019 |
Date | 2019-04-11 |
(87) | Number | WO 2019/200122 |
Date | 2019-10-17 |
(30) | Number | Date | Country code |
201862656809 P | 2018-04-12 | US |
(72) |
SMITH, James, Jefferson , US
LAPE, Janel , US
LI, Hui , US
GENSCHEL, Jochen , US
|
(73) |
Precision BioSciences, Inc. ,
302 East Pettigrew Street
Dibrell Building, Suite A-100, Durham, NC 27701,
US
|
(54) | OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE |
OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE |